DE:8F8 Stock Latest News
Company AnnouncementsSynAct Pharma CEO Acquires 20,313 Shares1d ago
Company AnnouncementsSten Sörensen Notifies SynAct Board of Decision to Resign1d ago
Company AnnouncementsSynAct Announces U.S. Patent Allowance for Resomelagon Tablet4d ago
Company AnnouncementsSynAct Pharma Plans Investor Conference Participation1w ago
Company AnnouncementsBioVal Initiates Coverage of SynAct Pharma2w ago
Company AnnouncementsSynAct Pharma Publishes Interim Report for January–September 20262w ago
Company AnnouncementsWHO Endorses SynAct Pharma’s Resomelagon as Key Dengue Drug Candidate2M ago
Company AnnouncementsSynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals2M ago
Company AnnouncementsSynAct Pharma Executives Sell Shares to Cover Danish Tax Liabilities2M ago
Company AnnouncementsSynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data2M ago
Company AnnouncementsSynAct Pharma Details 2026 First-Half Progress in Inflammatory Disease R&D2M agoCompany AnnouncementsSynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market3M ago
Company AnnouncementsSynAct Pharma Wins Key US Patent Ruling on Resomelagon Tablet Formulation3M ago
Company AnnouncementsSynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness4M ago
Company AnnouncementsSynAct preclinical data point to osteoarthritis potential for resomelagon4M ago
Company AnnouncementsSynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal4M ago
Company AnnouncementsSynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence5M ago
Company AnnouncementsSynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push5M agoCompany AnnouncementsSynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 20445M ago
Company AnnouncementsSynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch5M ago8F8





